Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

by Swann, Edith , Douoguih, Macaya , Goepfert, Paul A , Treanor, John , Van Hoof, Johan , Shukarev, Georgi , Robb, Merlin L , Sadoff, Jerald , Stoddard, Jeffrey , Le Gars, Mathieu , Vingerhoets, Johan , Neuzil, Kathleen M , Schuitemaker, Hanneke , Scheper, Gert , Barouch, Dan H , Hardt, Karin , Truyers, Carla , Corey, Lawrence , Struyf, Frank , Vandebosch, An , Ryser, Martin F , Cárdenas, Vicky , Van Dromme, Ilse , Gray, Glenda , Custers, Jerome , Grinsztejn, Beatriz , Spiessens, Bart , Ruiz-Guiñazú, Javier , Marovich, Mary A

in Ad26COVS1 - adverse effects / Ad26COVS1 - immunology / Adolescent / Adult / Confidence intervals / Coronavirus / Coronaviruses / COVID-19 / COVID-19 - epidemiology / COVID-19 - mortality / COVID-19 - prevention & control / COVID-19 vaccines / Death / Double-Blind Method / Follow-Up Studies / Hospitalization - statistics & numerical data / Humans / Immunogenicity, Vaccine / Infectious Disease / Kaplan-Meier Estimate / Middle Aged / Original / Patient Acuity / Placebos / Population / Questionnaires / Safety / SARS-CoV-2 / Severe acute respiratory syndrome coronavirus 2 / Vaccine efficacy / Vaccine Efficacy - statistics & numerical data / Vaccines / Young Adult

2022

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

2022

Confirm

Do you wish to request the book?

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

2022

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

Swann, Edith,

Douoguih, Macaya,

Goepfert, Paul A,

Treanor, John,

Van Hoof, Johan,

Shukarev, Georgi,

Robb, Merlin L,

Sadoff, Jerald,

Stoddard, Jeffrey,

Le Gars, Mathieu,

Vingerhoets, Johan,

Neuzil, Kathleen M,

Schuitemaker, Hanneke,

Scheper, Gert,

Barouch, Dan H,

Hardt, Karin,

Truyers, Carla,

Corey, Lawrence,

Struyf, Frank,

Vandebosch, An,

Ryser, Martin F,

Cárdenas, Vicky,

Van Dromme, Ilse,

Gray, Glenda,

Custers, Jerome,

Grinsztejn, Beatriz,

Spiessens, Bart,

Ruiz-Guiñazú, Javier,

Marovich, Mary A

2022

Overview

The randomized trial assessing the efficacy of a single injection of the Ad26.COV2.S showed 56.3% vaccine efficacy beginning 14 days after injection and 52.9% efficacy more than 28 days after injection against moderate to severe–critical Covid-19. Protection lasted at least 6 months without an added boost. Vaccination was associated with mild-to-moderate adverse effects.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Ad26COVS1 - adverse effects

/ Ad26COVS1 - immunology

/ Adolescent

/ Adult

/ Confidence intervals

/ Coronavirus

/ Coronaviruses